Investigational drug · Phase 2
OCU400
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Retinitis Pigmentosa, Leber Congenital Amaurosis.
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 31, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "OCU400"
First trial start
2022
Jan 24, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "OCU400", any sponsor or status.
Conditions studied
As listed on its trial records.
- Retinitis Pigmentosa
- Leber Congenital Amaurosis
Approved drugs for the same conditions: Rare and genetic disease · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "OCU400" as an intervention, largest first.
- Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital AmaurosisActive, not recruiting
OcugenIndustry
NCT05203939 · 22 participants · Start Jan 24, 2022 · Primary completion Mar 2027
Drug: OCU400 Low Dose; OCU400 Med Dose and 2 more · For: Retinitis Pigmentosa; Leber Congenital Amaurosis
Sites: Phoenix, Arizona; La Jolla, California; Miami, Florida · 7 sites in all
- Expanded Access Program for RP in AdultsNo longer available
OcugenIndustry
NCT06574997
Drug: OCU400 · For: Retinitis Pigmentosa
Sites: Phoenix, Arizona; Deerfield Beach, Florida; Erie, Pennsylvania · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Preclinical biodistribution and toxicology assessment of an AAV5-based subretinal modifier gene therapy for retinitis pigmentosa.
Upadhyay A, Drag S, Singh P, et al. · Front Med (Lausanne) 2025
- Genetic Therapies for Retinitis Pigmentosa: Current Breakthroughs and Future Directions.
Pniakowska Z, Dzieża N, Kustosik N, et al. · J Clin Med 2025
Also in development for Retinitis Pigmentosa
- BS01Phase 22 trials
Bionic Sight LLC · Retinitis Pigmentosa, Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD)
- CPK850Phase 21 trial
Novartis · Retinitis Pigmentosa
- famzeretcelhuman retinal progenitor cells, jCellPhase 21 trial
jCyte, Inc · Retinitis Pigmentosa
- KIO-301Phase 21 trial
Kiora Pharmaceuticals, Inc. · Retinitis Pigmentosa
- SPVN06Phase 21 trial
SparingVision · Retinitis Pigmentosa
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.